Accenture Invests in Geneyx to Expand the Use of Genetic Data for Targeted and Personalized Therapeutics and Diagnostics

Rhea-AI Summary

Accenture (NYSE: ACN) has strategically invested in Geneyx Genomex Ltd., an Israel-based developer of genomic analysis software. This investment aims to enhance patient outcomes in hereditary and rare diseases by providing AI-driven insights for risk prediction, diagnosis, and treatment. Geneyx's technology leverages whole-genome sequencing to improve clinical decision-making and accelerate the development of personalized therapies. This partnership aligns with Accenture's effort to boost innovation in the life sciences sector, connecting Geneyx to its INTIENT platform for improved collaboration and healthcare outcomes.

Positive

• Accenture's investment in Geneyx supports advancements in genomic analysis technology.
• Geneyx's AI platform enhances clinical decision-making through improved risk prediction and diagnostics.
• The partnership connects Geneyx to Accenture's INTIENT platform, fostering collaboration within the healthcare ecosystem.

Negative

• None.

NEW YORK--(BUSINESS WIRE)-- Accenture (NYSE: ACN) has made a strategic investment, through Accenture Ventures, in Geneyx Genomex Ltd. (Geneyx), an Israel-based developer of genomic analysis and interpretation software. Geneyx helps improve patient outcomes associated with hereditary and rare diseases by providing disease-specific, clinically relevant insights around risk prediction, diagnosis, prognosis, and treatment for clinical and pharmaceutical organizations.

Today, many patients receive standardized disease treatments which are safe and efficient, but not adaptive to an individual’s unique genetics. Through “New Science". biopharmaceutical companies have made considerable advances in developing targeted treatments, including cell and gene therapies, rapidly moving the industry toward individualized treatments and disease interventions. Yet, often, this data is siloed at hospitals and research institutions, hampering our collective understanding of disease biology and the development of more effective therapeutic options.

Geneyx’s AI-based platform is an example of New Science in action: it provides biomedical interpretation capabilities that better enables clinicians and researchers to use the power of whole-genome sequencing to advance human health. Geneyx technology leverages AI to improve risk prediction, diagnostic yield, prognostic prediction, and treatment insights supporting clinical decision-making and biopharmaceutical research, which help accelerate the development of targeted and personalized therapeutics.

Geneyx is also joining Accenture’s network of innovation partners connected to the INTIENT platform, which enables life science companies to advance the discovery, development and commercialization of New Science by connecting deeper intelligence to actions that improve outcomes. INTIENT helps clients achieve these goals by leveraging leading cloud-based technologies and an open partner network to improve collaboration between scientists, researchers and clinicians.

“We need to improve the treatment-cost equation from the current ways of operating to new ways of discovering, developing and commercializing treatments,” said Stuart Henderson, Accenture’s global lead of the Life Sciences industry group. “Geneyx is driving a model of collaboration to break down silos in the healthcare ecosystem to support the capture of the genetic data that will benefit each patient in their treatment journey.”

David Yizhar, Geneyx CEO and co-founder, added, “Accenture’s investment and support will enable Geneyx to accelerate the adoption of our AI-based genomic interpretation technology on a global scale helping to leverage insights from siloed genetic data around the world and powering clinical research and pharmaceutical discovery.”

Geneyx is part of Accenture Ventures’ Project Spotlight, an engagement and investment program that connects emerging technology software startups with the Global 2000 to fill strategic innovation gaps. Project Spotlight offers extensive access to Accenture’s domain expertise and its enterprise clients, helping startups harness human creativity and deliver on the promise of their technology. Geneyx is also the latest addition to the investment portfolio of Accenture Ventures, which is focused on investing in companies that create or apply disruptive enterprise technologies.

“Accenture’s investment in Geneyx reflects our ongoing commitment to strengthening companies with the potential to transform their industries,” said Tom Lounibos, managing director of Accenture Ventures. “Geneyx is well-positioned to make meaningful impact in clinical genetic data analysis, ultimately helping more patients in need. We are excited to support them on this important journey.”

Terms of the investment were not disclosed.

Accenture’s Life Sciences industry group helps pharmaceutical, biotech, medical technology, distributor and consumer health companies combine the latest technology with scientific breakthroughs to revolutionize how medical treatments are discovered, developed and delivered to patients around the world. To learn more, visit https://www.accenture.com/us-en/industries/life-sciences-index.

About Accenture
Accenture is a global professional services company with leading capabilities in digital, cloud and security. Combining unmatched experience and specialized skills across more than 40 industries, we offer Strategy and Consulting, Interactive, Technology and Operations services — all powered by the world’s largest network of Advanced Technology and Intelligent Operations centers. Our 624,000 people deliver on the promise of technology and human ingenuity every day, serving clients in more than 120 countries. We embrace the power of change to create value and shared success for our clients, people, shareholders, partners and communities. Visit us at www.accenture.com.

About Geneyx
Geneyx offers a superior NGS data analysis and interpretation platform, harnessing genetic data to guide digital insights for rare and germline disorders. Our AI-based analysis platform streamlines the diagnostics process, from the raw genetic data to the final clinical report. Geneyx develops unique technologies and utilizes diverse databases in the interpretation of WGS (whole-genome sequencing), WES (whole-exome sequencing), and gene panels. For more information visit To learn more visit https://geneyx.com.

Copyright ©2021 Accenture. All rights reserved. Accenture and its logo are registered trademarks of Accenture

View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005593/en/

Marchell Gillis

Accenture

+1 678 657 7515 (office)

+1 404 409 9430 (mobile)

marchell.gillis@accenture.com

Source: Accenture

FAQ

What recent investment did Accenture make related to genomics?

Accenture recently invested in Geneyx Genomex Ltd., enhancing its capabilities in genomic analysis.

How does Geneyx contribute to personalized medicine?

Geneyx provides AI-driven insights for risk prediction and treatment, advancing personalized therapeutic options.

What is the significance of Accenture's investment in Geneyx?

The investment reflects Accenture's commitment to innovation in life sciences and improving patient outcomes.

When was the investment in Geneyx announced?

The investment by Accenture in Geneyx was announced on November 9, 2021.

What is Geneyx's technology focused on?

Geneyx focuses on genomic analysis and interpretation, particularly for hereditary and rare diseases.